Viking Therapeutics Inc. (VKTX) exhibits 44.0% gross margins and -35.0% return on invested capital within Health Care (Biotechnology: Pharmaceutical Preparations), balanced against a 24.0x enterprise multiple and 6.6% implied options volatility.
Sustained 44.0% gross profitability converts into 16.5% operating margin and -35.0% ROIC, outpacing sector cost of capital.
ROIC: -35.0% // GM: 44.0%YoY revenue trajectory of +15.4% paired with -8.25% free cash flow yield supports self-funded R&D and capital return.
REV YOY: +15.4% // FCF YLD: -8.25%Altman Z-Score of 24.02 and Piotroski F-Score of 5/9 indicate low near-term refinancing stress.
ALTMAN Z: 24.02 // F-SCORE: 5/9Trading at 24.0x trailing P/E (35.0x Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.
P/E: 24.0x // EV/EBITDA: —Options market prices a ±6.6% implied move with a 0.68 put/call ratio around $26.00 max pain.
IMPL MOVE: ±6.6% // P/C: 0.68Elevated industry capital intensity and customer concentration in Biotechnology: Pharmaceutical Preparations require continuous execution to defend 12.4% net margins.
NET MARGIN: 12.4% // D/E: 0.05x| FILER | SIDE | $ VALUE |
|---|---|---|
| INSPECT FULL OWNERSHIP LEDGER IN OWN <GO> | ||
| STRIKE / EXP | TYPE | PREMIUM |
|---|---|---|
| INSPECT GEX & CHAIN IN OPT <GO> | ||
Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for VKTX & activate live FRED threshold breach alerts.